Minnesota Oncology is an independent, community-based cancer care practice providing patient-centered, evidence-based treatment in the Twin Cities metro area. Minnesota Oncology patients have access to more than 100 cancer care experts, evidence-based treatment paths, clinical trials, 12 close-to-home locations and comprehensive services to support the whole person.
Minnesota Oncology is a practice in The US Oncology Network (The Network). The practices in The Network comprise more than 1,380 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Minnesota Oncology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.
Dr Paul Forsberg Highlights the Role of the Reference Product Once Biosimilars Hit the MarketOctober 16th 2022
Biosimilars have had such an impact on driving down costs, that in some instances the reference product might be the lowest cost option, explained Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Considering When to Switch Patients From One Biosimilar to AnotherOctober 9th 2022
With more and more biosimilars reaching market, there are considerations around whether to keep patients on their current biosimilar or switch them to another biosimilar as the market dictates, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Dr Paul Forsberg: Ensuring Consistent, Clear Messaging Critical During Biosimilar ConversionSeptember 25th 2022
When converting a patient to a biosimilar, having clear and consistent messaging will reduce confusion and prevent patients from having a lack of trust in the process, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
The Biosimilar Conversion Journey Went Through 2 Phases at Minnesota OncologySeptember 4th 2022
While initially there was a need for education around biosimilars, now there is a need to keep an eye on the evolving biosimilar marketplace and update the formulary of biosimilar medicines, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Telehealth at Minnesota Oncology: Tackling COVID-19, Educating Patients, and Overcoming the WeatherFebruary 14th 2022
Rajini Katipamula-Malisetti, MD, a medical oncologist and hematologist with Minnesota Oncology who practices in Coon Rapids, has seen telehealth’s usefulness up close. During a pandemic, it can increase the number of touch points in areas such as survivorship care and nutrition, which would otherwise require a separate visit to the office.
Panel Discusses the Ongoing Evolution of Remote Patient CareDecember 19th 2021
The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.